Veradermics (MANE) reported a Q3 net loss of $ 21.0 million on Tuesday, widening from a $20.1 million net loss a year earlier.
Analysts polled by FactSet expected losses of $26.5 million.
The company reported no revenue for the quarter ended Sept. 30, as expected by analysts.
The biopharmaceutical startup reported cash and cash equivalents totaling $798.4 million as of Sept. 30, up from $141.9 million on Dec. 31, enough to sustain operations into 2030.
Shares of the company were up 1.1% in Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments